HBOT for POTS and Dysautonomia: The 2026 Evidence Atlas (Investigational Use)

Hyperbaric oxygen therapy (HBOT) is sometimes pitched as a fix for POTS and other forms of dysautonomia, especially in long-COVID circles. The honest answer in 2026 is that no large, high-quality trial has tested HBOT directly on POTS, and the closest evidence we have is mixed at best. This atlas lays out exactly what the research shows, where the gaps are, and how HBOT stacks up against treatments that actually have data behind them.

What POTS and Dysautonomia Actually Are

Dysautonomia is an umbrella term for any disorder of the autonomic nervous system, the part of your body that runs automatic functions like heart rate, blood pressure, digestion, and temperature control. When that system misfires, the symptoms can be wide-ranging and hard to pin down.

Postural orthostatic tachycardia syndrome (POTS) is the most talked-about form. The defining feature is simple to measure: when you stand up, your heart rate jumps by at least 30 beats per minute (40 bpm for teenagers) within 10 minutes, without a big drop in blood pressure. According to the National Institute of Neurological Disorders and Stroke, the racing heart usually comes with lightheadedness, fatigue, brain fog, palpitations, and exercise intolerance.

POTS is not one disease with one cause. The Cleveland Clinic describes several recognized subtypes, including:

• Hypovolemic POTS — low blood volume
• Neuropathic POTS — small-fiber nerve damage affecting blood vessel tone in the legs
• Hyperadrenergic POTS — an overactive sympathetic ("fight or flight") response
• Secondary POTS — linked to another condition like autoimmune disease, diabetes, or a recent viral infection

This matters for the HBOT question. A therapy that might help one subtype could do nothing for another. "POTS" as a single target for HBOT is too blunt a concept to study cleanly, which is part of why the research is so thin.

Dysautonomia also goes far beyond POTS. It includes orthostatic hypotension (blood pressure drops on standing), neurocardiogenic syncope (fainting), inappropriate sinus tachycardia, and autonomic neuropathies tied to diabetes, Parkinson's disease, or autoimmune conditions. When someone searches for "HBOT for dysautonomia," they could mean any of these, and the evidence for HBOT is essentially absent for every one of them. The few HBOT studies that touch the autonomic nervous system at all were done in unrelated populations, like healthy volunteers or carbon monoxide poisoning survivors, not in people with a primary dysautonomia diagnosis.

Why the COVID Connection Drives the HBOT Hype

POTS cases climbed sharply after 2020. A 2024 review in Annals of Allergy, Asthma & Immunology notes that post-COVID dysautonomia, often showing up as POTS, "markedly affects patient quality of life and ability to return to work," and that the true prevalence is still unknown because of referral bias and inconsistent definitions (Tavee, 2024). Because HBOT was studied as a long-COVID treatment, and because long COVID and POTS overlap, HBOT got swept into the POTS conversation. That overlap is the main reason the topic exists at all, and it shapes almost all the evidence we have.

How HBOT Is Supposed to Help (The Theory)

HBOT means breathing close to 100% oxygen inside a pressurized chamber, usually at 2.0 to 2.4 times normal atmospheric pressure (ATA). At that pressure, oxygen dissolves directly into blood plasma, raising tissue oxygen levels far beyond what normal breathing allows.

The proposed mechanisms for dysautonomia are all indirect. None of them is proven to fix POTS:

• Reducing neuroinflammation. Some researchers think post-viral dysautonomia is driven by low-grade inflammation in the brainstem and autonomic nerves. HBOT has anti-inflammatory effects in other settings, so the idea is it might calm that down.
• Improving small-vessel function. HBOT can stimulate angiogenesis (new blood vessel growth) and improve microvascular flow. Since neuropathic POTS involves poor blood vessel control, better microcirculation is the theoretical target.
• Shifting autonomic balance. A few small studies show HBOT can change heart rate variability, a marker of autonomic function. Whether that shift is helpful for POTS specifically is unknown.

The gap between "HBOT does X in a lab" and "HBOT helps POTS patients feel better" is enormous. Every mechanism above is a hypothesis, not a result.

It's also worth noting a tension inside the theory itself. POTS at its core is a problem of heart-rate control on standing, often with too much sympathetic drive. If HBOT mostly nudges sympathetic activity, as one heart rate variability study suggests, it's not obvious that would help a hyperadrenergic POTS patient. It might even point the wrong way. The mechanisms that sound appealing in a brochure don't line up neatly with what's actually broken in most POTS subtypes. That mismatch is a reason for caution, not optimism.

One more theory deserves a flag because it shows up in marketing: the claim that POTS is simply a problem of "not enough oxygen reaching the brain" and that flooding the body with oxygen fixes it. That's a misreading. In POTS, the issue is usually how blood is distributed and how the heart rate responds to standing, not a shortage of oxygen in the blood itself. Most POTS patients have normal blood oxygen levels. Pumping in more oxygen does not address the underlying autonomic signaling problem.

The Actual Evidence: What Has Been Tested

Here is the core problem. As of mid-2026, there is no randomized controlled trial of HBOT with POTS or a defined dysautonomia diagnosis as the primary condition being treated. What exists is a handful of studies in overlapping populations, plus tiny case observations. Below is the honest grade.

The Single Most Important Data Point

The HOT-LoCO randomized trial is the highest-quality study touching this space. It enrolled 80 long-COVID patients, randomized them to 10 sessions of real HBOT (2.4 bar, 90 minutes, 100% oxygen) or convincing sham (medical air at low pressure), and kept everyone blinded. The result: at 13 weeks, there was no significant difference between HBOT and placebo on the primary physical-function endpoints. Both groups got better, which points to natural recovery and placebo response rather than a true HBOT effect.

This is the kind of trial design that catches false hope. When a well-blinded study shows the placebo group improving just as much, it usually means the treatment is not doing the heavy lifting. POTS was not the formal endpoint, but a large share of long-COVID patients have POTS-type symptoms, so the signal is hard to ignore.

Why the "Positive" Studies Don't Close the Case

Two studies often get cited as wins. Read them carefully:

• The myocardial-function RCT used 40 sessions and found real improvement in a heart-muscle measurement (global longitudinal strain). That is a structural cardiac finding, not a measure of orthostatic heart-rate jump or POTS symptoms. It does not tell us whether anyone's POTS got better.
• The HRV study found HBOT nudged some autonomic markers in 14 healthy young men. Notably, it changed sympathetic indices but not vagal ones, and these were healthy volunteers, not patients. A marker moving is not a symptom resolving.

Put bluntly: the strongest direct evidence (a real RCT in the most relevant population) was negative, and the supportive studies measure things that aren't POTS.

What About Case Reports and Clinic Testimonials?

Search hard enough and you'll find individual patients who say HBOT helped their POTS, and clinics happy to amplify those stories. Take them seriously as personal experience, but understand their limits as evidence.

POTS, especially post-viral POTS, frequently improves on its own over months to a couple of years. When someone does 40 HBOT sessions over two months and feels better afterward, there's no way to know whether HBOT did it, whether they were recovering anyway, or whether the structure of regular appointments, gentle activity, and hope drove a placebo response. The blinded HOT-LoCO trial showed exactly this trap: the sham group improved just as much as the treatment group. Testimonials can't separate the treatment from the natural course of the illness. That's the entire reason controlled trials exist.

The weakest tier of evidence in the table above, the paroxysmal sympathetic hyperactivity case series, is a useful illustration. It involved just three patients with a completely different disorder (sympathetic storms after carbon monoxide poisoning, where HBOT is already standard for the poisoning itself). It tells us nothing reliable about POTS. Yet a paper like this can get cited loosely as "HBOT helps the sympathetic nervous system." Reading the actual study is the only way to catch that gap.

Honest Evidence Grade

Using a plain grading scale, here's where HBOT for POTS and dysautonomia sits in 2026:

HBOT is investigational for POTS and dysautonomia. That is not a hostile label. It simply means the evidence has not crossed the bar that proven treatments clear. Anyone selling it as an established POTS cure is ahead of the data.

Regulatory Reality: HBOT Is Not Approved for POTS

Neither the FDA nor the Undersea and Hyperbaric Medical Society lists any autonomic disorder among approved HBOT uses.

The FDA has cleared HBOT for a specific set of conditions, none of which is POTS or dysautonomia. The agency's letter to health care providers explicitly warns that many marketed HBOT claims are unproven and that devices should be used under a doctor's care at an accredited facility. The UHMS list of approved indications covers wounds, infections, carbon monoxide poisoning, decompression sickness, and similar conditions, again with no autonomic disorder on it.

So when a clinic treats POTS with HBOT, it is doing so off-label. Off-label use is legal for licensed physicians, but it means insurance will not cover it, and it shifts the burden of proof onto the clinic to justify the treatment. For more on the line between legal and evidence-based, see our guide on off-label HBOT: legal vs evidence-based.

How HBOT Compares to Treatments That Actually Work for POTS

This is where the comparison gets uncomfortable for HBOT. POTS has a recognized, evidence-supported management ladder, summarized in clinical reviews like the management framework for postural tachycardia syndrome. None of it involves HBOT.

The first-line approach is almost always non-drug:

• Volume expansion — increasing fluid intake (often 2–3 liters per day) and salt intake to raise blood volume
• Compression garments — waist-high compression to reduce blood pooling in the legs
• Graded exercise — structured, recumbent-to-upright reconditioning programs (rowing, recumbent bike, swimming) that are among the best-supported interventions
• Avoiding triggers — heat, big meals, prolonged standing, deconditioning

When those aren't enough, doctors may add medications such as beta-blockers, ivabradine, midodrine, or fludrocortisone, chosen by subtype. Every one of these has more direct evidence for POTS than HBOT does.

The practical takeaway: HBOT, if used at all, belongs after the proven basics, not instead of them. Spending thousands on hyperbaric sessions while skipping salt, fluids, compression, and graded exercise is backwards.

Here is a side-by-side of where HBOT sits against the standard options:

The contrast is stark. The proven options are cheap and often covered. HBOT is the most expensive item on the list and the only one with no established role.

Cost and Practical Considerations

Because HBOT for POTS is off-label, you pay out of pocket. Clinic-based medical HBOT runs roughly $200 to $600 per session, and the protocols floated for post-viral conditions often involve 40 sessions, putting a full course in the $8,000 to $24,000 range. Mild home or "soft-shell" chambers (1.3 ATA) are cheaper per use but deliver far less oxygen and have even weaker evidence for anything beyond relaxation. Our HBOT cost guide breaks the numbers down by setting.

Before spending anything, it's worth understanding the gap between hard medical chambers and soft chambers, since the marketing around POTS often blurs them. Our explainer on mild HBOT vs medical HBOT and why 1.3 ATA is controversial covers why the pressure number matters.

Safety: What the Trials Actually Reported

HBOT is reasonably safe in trained hands, and the long-COVID RCT supports that. In HOT-LoCO, adverse events were common but mostly minor (cough and chest discomfort) and occurred at similar rates in the HBOT and placebo groups (49% vs 44%). The authors concluded HBOT "has a favourable harm profile."

That said, real risks exist and matter more for some POTS patients:

• Ear and sinus barotrauma — the most common side effect, from pressure changes
• Temporary nearsightedness — vision can shift after many sessions, usually reversing over weeks
• Oxygen toxicity seizures — rare but serious, from breathing high-pressure oxygen
• Confinement anxiety — being in a sealed chamber can be hard, and anxiety-driven tachycardia can mimic or worsen POTS symptoms in some people
• Fire risk — high-oxygen environments are flammable, which is why accredited facilities ban certain materials inside

People with POTS often have overlapping conditions (anxiety, mast cell issues, connective tissue disorders) that can complicate HBOT. A medical evaluation first is non-negotiable. Our HBOT contraindications guide lists who should not enter a chamber at all.

Who Might Reasonably Consider It (and Who Shouldn't)

HBOT for POTS is a maybe, not a recommendation. If you're weighing it:

It might be worth a conversation with a specialist if:

• You have post-viral POTS or long COVID and have already tried the proven basics (fluids, salt, compression, graded exercise, appropriate medication) without enough relief
• You can afford it without financial strain, understanding insurance won't pay
• You're being treated by a physician who is honest that this is experimental, not a cure
• You're enrolled in or near a legitimate clinical trial

It's probably not for you if:

• You haven't tried first-line POTS management yet
• A clinic is promising it will "cure" your POTS or guaranteeing results
• You have contraindications like certain lung conditions or untreated pneumothorax
• The cost would mean skipping proven care

The most defensible path is to treat HBOT as a possible add-on at the far end of the ladder, with eyes open about thin evidence, and only at an accredited center.

Related Reading

• Off-Label HBOT: Legal vs Evidence-Based
• HBOT for Long COVID: A Detailed Analysis of the Shamir RCT
• HBOT for Chronic Fatigue Syndrome
• HBOT Contraindications: When It's Genuinely Dangerous
• How Much Does HBOT Cost in 2026?

Frequently Asked Questions

Is HBOT FDA-approved for POTS or dysautonomia?

No. The FDA has not cleared hyperbaric oxygen therapy for POTS or any autonomic disorder, and the UHMS list of approved indications does not include them. Any clinic treating POTS with HBOT is doing so off-label, which means insurance won't cover it and the treatment is experimental.

Does HBOT cure POTS?

There is no good evidence that HBOT cures POTS. No randomized trial has tested it with POTS as the target condition, and the most relevant high-quality study (the HOT-LoCO long-COVID RCT) found no significant benefit over placebo on its main endpoints. Be skeptical of any clinic promising a cure.

Why do people with long COVID try HBOT for POTS symptoms?

Long COVID and POTS overlap heavily, and HBOT was studied as a long-COVID treatment, so the two topics got linked. A 2024 review notes only "marginal" benefit from HBOT for post-COVID brain fog and makes no POTS-specific efficacy claim (Tavee, 2024). The interest is real, but the proof is not there yet.

What treatments for POTS actually have evidence?

The proven approach is non-drug first: increased fluids and salt, compression garments, and graded exercise reconditioning, as outlined in POTS management reviews. Medications like beta-blockers, ivabradine, midodrine, and fludrocortisone are added based on the POTS subtype. All of these have more direct support than HBOT.

Is HBOT safe for someone with POTS?

In trials, HBOT had a favorable harm profile, with side effects (mostly cough and chest discomfort) similar to placebo. But risks like ear barotrauma, temporary vision changes, rare oxygen-toxicity seizures, and confinement anxiety are real, and anxiety-driven tachycardia could worsen POTS symptoms in some people. A medical evaluation and an accredited facility are essential before trying it.

This article is for informational purposes only and is not medical advice. POTS and dysautonomia require diagnosis and management by a qualified healthcare provider. Do not start, stop, or change any treatment based on this content without consulting your physician.

-- The HBOT Finder Team